Alzheimer’s disease gaining recognition as researchers and pharma companies work to find therapy

WORLD– According to World Health Organization (WHO), Alzheimer’s disease attributes to around 60-70 % cases of dementia cases globally. WHO projects that by the year 2030, 82 million cases of Dementia will be recorded which will nearly double by the year 2050 hence more cost of treatment which currently stands at US$818Bper annum, equivalent to 1.1% of global gross domestic product (GDP). The disease currently has no cure and has prompted researchers and pharma-based companies to work a way on how to develop its therapy as also a measure to…

Read More

FDA grants approval for ADUHELM as the first and only Alzheimer’s disease treatment

USA – U.S. Food and Drug Administration has approved Biogens’ Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans, the first new treatment approved for Alzheimer’s since 2003. Aduhelm has been approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments. Currently available therapies only treat symptoms of the disease whereas this treatment option is the first therapy to target and affect the underlying disease process of…

Read More